EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY-NC-ND 4.0

VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results

Peter A Leone, Alejandro Ferro, Charlotte-Paige Rolle iD, Sergio Lupo, Joseph McGowan, Marina Klein iD, Pedro Cahn iD, Paul Benson, Rulan Griesel, Michael Warwick-Sanders, Marisa Sanchez, Riccardo D'Agostino und 10 weitere

The Journal of Infectious Diseases · 2025

DOI: 10.1093/infdis/jiaf450 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Peter A Leone und 21 weiteren Autor:innen. Beteiligte Einrichtung: ViiV Healthcare, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: HIV Infections, HIV-1, Anti-HIV Agents, HIV Antibodies. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

VH3810109 (N6LS) is a CD4-binding site antibody with broad and potent neutralizing activity in vitro. Here, we present efficacy, safety, and pharmacokinetic results from the phase 2a BANNER study in people with HIV-1.

Methods

BANNER was a randomized, open-label, 2-part, multicenter study of N6LS in adults naive to antiretroviral therapy (ART) with HIV-1 RNA ≥5000 copies/mL. N6LS was evaluated during monotherapy after a single intravenous (IV) infusion at various doses or subcutaneous (SC) injection, followed by 48 weeks of standard-of-care ART. Antiviral activity, safety, pharmacokinetics, and antidrug antibodies (ADAs) were evaluated.

Results

Sixty-two participants completed the monotherapy phase and 58 completed the standard-of-care phase. Most participants were male (94%), Hispanic (82%), and White (61%). Virologic response (reduction in HIV-1 RNA ≥0.5 log10 copies/mL from baseline) was achieved in 8/8 (100%; 40 mg/kg IV), 14/15 (93%; 700 mg IV), 5/6 (83%; 280 mg IV), 7/16 (44%; 70 mg IV), and 8/16 (50%; 700 mg SC) participants. Administered IV or SC, N6LS was well tolerated with few drug-related adverse events (n = 13) and no serious adverse events reported during monotherapy. Pharmacokinetic parameters increased proportionally with dose. Incidence of ADAs was dose-dependent and ranged from 6% to 83% in the IV groups; incidence was 19% in the SC group, with no indication that route of administration impacts incidence of ADAs.

Conclusions

N6LS was efficacious and generally safe, supporting further development of N6LS dosed IV or SC for the treatment of HIV-1 (ClinicalTrials.gov, NCT04871113).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1Anti-HIV AgentsHIV AntibodiesAntibodies, NeutralizingAntibodies, MonoclonalHumansMaleAdultFemaleMiddle AgedViral LoadRNA, ViralTreatment OutcomeAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

CD4-binding siteN6LSantidrug antibodiesbNAbpharmacokinetics

Substanzen

Anti-HIV AgentsHIV AntibodiesRNA, ViralAntibodies, NeutralizingAntibodies, MonoclonalleronlimabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • ViiV Healthcare, Durham, North Carolina, USA.
  • Infectología, Centro de Investigaciones Médicas, Mar del Plata, Argentina.
  • Research Operations, Orlando Immunology Center, Orlando, Florida, USA.
  • CAICI, Rosario, Argentina.
  • Infectious Disease, Northwell Health, New York, New York, USA.
  • Department of Medicine, McGill University Health Centre, Montréal, Québec, Canada.

ORCID-Profile: Charlotte-Paige Rolle, Marina Klein, Pedro Cahn, Margaret Gartland

Förderung

  • ViiV Healthcare

Zitieren

APA

Leone, P. A., Ferro, A., Rolle, C. P., Lupo, S., McGowan, J., Klein, M., Cahn, P., Benson, P., Griesel, R., Warwick-Sanders, M., Sanchez, M., D'Agostino, R., Bettacchi, C., Schneider, S., Wannamaker, P., Dorey, D., Wilches, V., Gartland, M., Brown, K., …, & Losos, J. (2025). VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf450

Vancouver

Leone PA, Ferro A, Rolle CP, Lupo S, McGowan J, Klein M, et al. VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf450

BibTeX
@article{Leone2025,
  author = {Leone, Peter A and Ferro, Alejandro and Rolle, Charlotte-Paige and Lupo, Sergio and McGowan, Joseph and Klein, Marina and Cahn, Pedro and Benson, Paul and Griesel, Rulan and Warwick-Sanders, Michael and Sanchez, Marisa and D'Agostino, Riccardo and Bettacchi, Christopher and Schneider, Stefan and Wannamaker, Paul and Dorey, David and Wilches, Viviana and Gartland, Margaret and Brown, Kathryn and Gandhi, Yash and Donatti, Christina and Losos, Jan},
  title = {VH3810109 Efficacy, Safety, Pharmacokinetics, and Incidence of Antidrug Antibodies in Adults With HIV-1 Naive to Antiretroviral Therapy: BANNER Study Results},
  journal = {The Journal of Infectious Diseases},
  year = {2025},
  doi = {10.1093/infdis/jiaf450}
}
Kostenlos starten →